News

Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Fierce Biotech1d
Eli Lilly's phase 1 amylin data impress analysts, pairing 11% weight loss with tolerable profile
Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...
Eli Lilly files lawsuits over other companies selling Zepbound and Mounjaro
INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...
PharmExec10h
Eli Lilly to Acquire Verve Therapeutics for $1 Billion
With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...
Fierce Pharma1d
Eli Lilly adds high-dose Zepbound options to lineup of cheaper vials available on self-pay website
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...